Over the past decades, systemic treatment strategies involving epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have greatly improved outcomes and represent the backbone of treatment for advanced EGFR-mutant non-small-cell lung cancer (NSCLC) (1, 2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.